Prostate tumor overexpressed-1, in conjunction with human papillomavirus status, predicts outcome in early-stage human laryngeal squamous cell carcinoma

Abstract

// Lin Yang 1,2,3,* , Hongzhi Wang 1,2,3,* , Yan Wang 1,2,3 , Zhenyu He 1,2,3 , Haiyang Chen 4 , Shaobo Liang 5 , Shasha He 1,2,3 , Shu Wu 1,2,3 , Libing Song 1,2,3 and Yong Chen 1,2,3 1 Sun Yat-Sen University Cancer Center, Guangzhou, China 2 State Key Laboratory of Oncology in Southern China, Guangzhou, China 3 Collaborative Innovation Center for Cancer Medicine, Guangzhou, China 4 The Six Affiliated Hospital of Sun Yat-sen University, Guangzhou, China 5 The First Hospital of Foshan, Foshan, China * These two authors contributed equally to this work Correspondence to: Yong Chen, email: // Keywords : prostate tumor overexpressed-1, laryngeal squamous cell carcinoma, prognosis, HPV, biomarker Received : September 16, 2015 Accepted : March 01, 2016 Published : March 15, 2016 Abstract In human cancer, molecular markers combined with clinical characteristics are used increasingly to predict prognosis. Prostate tumor overexpressed-1 (PTOV1), first identified in prostate cancer, is a key factor in tumor progression and correlates with unfavorable clinical outcomes. HPV infection status was tested by HPV E6-targeted multiplex real-time PCR and p16 immunohistochemistry (IHC). Real-time PCR and western blotting analyses were used to examine the mRNA and protein expression levels of PTOV1 in eight paired LSCC samples. IHC was performed to assess PTOV1 protein expression in 196 paraffin-embedded, archived LSCC samples. PTOV1 protein and mRNA expression was increased in LSCC tissues compared with adjacent non-cancerous tissue samples. High expression of PTOV1was significantly associated with advanced TNM stage by the χ 2 test. Multivariate analysis revealed that PTOV1 and HPV status were independent prognostic indicators of overall survival (OS) and progression-free survival (PFS) ( P = 0.001, P = 0.009 for OS, P = 0.005, P = 0.012 for PFS, respectively). Our study provides the first evidence that the combination of PTOV1 expression level and HPV status provides more prognostic information compared with HPV status alone with the significance still exists in the HPV negative subgroup.